The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Amirata Saei Dibavar, assistant professor at the Department of Microbiology, Tumor and Cell Biology has been awarded the Novo ...

"This is a situation where, had Novo Nordisk done the appropriate work upfront ... obtain statistical significance without a very large sample size. Engel is represented by Motley Rice, a firm ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

Eptinezumab use improves quality-of-life measures but does not significantly reduce the number of episodic cluster headache ...

The Obesity Drugs Market is experiencing unprecedented growth, driven by increasing global obesity rates, sedentary ...

CALIFORNIA, CA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- The Type 2 Diabetes market is undergoing significant ...

In the wake of early evidence supporting the long-term health benefits of GLP-1 based medications to potentially reduce the ...

The global drug device combination products market, valued at US$224.70 billion in 2024, stood at US$243.02 billion in 2025 ...

In a retrospective cohort study using propensity matching, among patients with obesity, those taking semaglutide had lower ...

Internationally, the scale is far smaller. There is not a single public company outside the US currently worth $1 trillion.

For patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease, 10-year data from the ...